Physician profile
Sharon Cooperman
NPI 1972751238
$1,657.64
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $1,512.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,128.63 | 2020 | |
| Neurocrine Biosciences, INC. | $129.01 | 2020 | |
| Novartis Pharmaceuticals Corporation | $88.72 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $84.13 | 2019 | |
| Biogen, INC. | $37.01 | 2020 | |
| Vertical Pharmaceuticals, LLC | $30.24 | 2019-2020 | |
| Nuvasive, INC. | $23.91 | 2020 | |
| Ucb, INC. | $21.75 | 2020 | |
| Amgen INC. | $21.57 | 2020 | |
| Sunovion Pharmaceuticals INC. | $19.83 | 2020 | |
| Acorda Therapeutics, INC | $17.53 | 2020 | |
| Tanabe Pharma America, INC. | $15.06 | 2019 | |
| Allergan, INC. | $15.05 | 2019 | |
| Lilly USA, LLC | $12.94 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.26 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Cooperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.